Summary of FDA antibody-mediated rejection workshop (Q42598786)

3 November 2017

title

Summary of FDA antibody-mediated rejection workshop (English)

1 reference

3 November 2017

0 references

1 reference

P Archdeacon

1

1 reference

3 November 2017

M Chan

2

1 reference

3 November 2017

C Neuland

3

1 reference

3 November 2017

E Velidedeoglu

4

1 reference

3 November 2017

J Meyer

5

1 reference

3 November 2017

L Tracy

6

1 reference

3 November 2017

M Cavaille-Coll

7

1 reference

3 November 2017

S Bala

8

1 reference

3 November 2017

A Hernandez

9

1 reference

3 November 2017

R Albrecht

10

1 reference

3 November 2017

language of work or name

English

0 references

publication date

1 May 2011

1 reference

American Journal of Transplantation

3 November 2017

published in

1 reference

3 November 2017

volume

11

1 reference

3 November 2017

issue

5

1 reference

3 November 2017

page(s)

896-906

1 reference

Humoral rejection of organ allografts

3 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03525.X

Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03525.X

Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03525.X

Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03525.X

Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03525.X

Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03525.X

Strategies for human leukocyte antigen antibody detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03525.X

Production of alpha-1,3-galactosyltransferase null pigs by means of nuclear transfer with fibroblasts bearing loss of heterozygosity mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03525.X

Immunotoxin-treated rhesus monkeys: a model for renal allograft chronic rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03525.X

Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03525.X

C4d staining of renal allograft biopsies: a comparative analysis of different staining techniques

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03525.X

Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03525.X

Antibody-mediated rejection in renal allografts: lessons from pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03525.X

Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03525.X

The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03525.X

World apheresis registry 2003-2007 data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03525.X

Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03525.X

Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03525.X

Beyond histology: lowering human leukocyte antigen antibody to improve renal allograft survival in acute rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03525.X

Combination of peritubular c4d and transplant glomerulopathy predicts late renal allograft failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03525.X

Four stages and lack of stable accommodation in chronic alloantibody-mediated renal allograft rejection in Cynomolgus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03525.X

Acute humoral rejection in renal allograft recipients: I. Incidence, serology and clinical characteristics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03525.X

Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03525.X

Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03525.X

Treatment of C4d-positive acute humoral rejection with plasmapheresis and rabbit polyclonal antithymocyte globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03525.X

Rituximab as treatment for refractory kidney transplant rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03525.X

Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03525.X

Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03525.X

Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03525.X

Long-term experience of plasmapheresis in antibody-mediated rejection in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03525.X

10.1111/J.1600-6143.2011.03525.X

21 January 2018

Identifiers

DOI

1 reference

3 November 2017

1 reference